FDA Clears IND for OcuRing™-K, Paving Way for Phase II Cataract Surgery Trial
PRFX is trading near its 52-week low of $0.912 (9.9% above the low).
Summary
PRF Technologies announced FDA clearance of its IND for OcuRing™-K, enabling a multi-center Phase II trial in cataract surgery with enrollment expected in H2 2026. The company also reported PRF-110 demonstrated 72-hour analgesic activity comparable to ZYNRELEF® in a preclinical model using a ropivacaine-only, NSAID-free formulation. Balance sheet strengthened to $11.6 million in cash as of June 30, 2026, nearly triple year-end 2025 levels, following a $10 million raise in May. G&A expenses fell 39% year-over-year while R&D investment nearly tripled. DeepSolar began generating revenue from commercial engagements and entered a collaboration with Blade Ranger targeting enterprise deals of at least 150 MW each. The IND clearance is a significant regulatory milestone for the company's lead ophthalmology asset, and the comparative analgesic data supports advancement of PRF-110 as a non-opioid post-surgical pain option. Phase II enrollment timing and initial DeepSolar revenue traction are key near-term watchpoints.
At the time of this announcement, PRFX was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.91 to $9.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.